NCT05019287 - Menstrual Blood Stem Cells in Severe Covid-19 | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 17, 2021

Primary Completion Date

May 21, 2021

Study Completion Date

June 9, 2021

Conditions

Covid19Cytokine Storm

Interventions

BIOLOGICAL

Allogeneic human menstrual blood stem cells secretome

This COVID-19 Study intervention consists of Intravenous Allogeneic human menstrual blood stem cell (MenSC) secretome injection in addition to standard care. The MenSC were characterized as CD90+, CD73+, CD105+, and CD45-based on multiparameter flow cytometry.

OTHER

Intravenous saline injection

Intravenous saline injection in addition to standard care

Trial Locations (1)

Unknown

Avicenna Research Institute, Tehran